Primary Mediastinal Large B-cell Lymphoma (PMBCL)
23
13
17
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 23 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (23)
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Bio-CAR-T BS Study
SynKIR-310 for Relapsed/Refractory B-NHL
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
Italian Observational Study on CAR-T Therapy for Lymphoma
Expanded Access Program for Epcoritamab
CAR T Cell Therapy Related Cardiovascular Outcomes